SUPPORTING INFORMATION

Ultrasonic-Assisted Solid-Phase Peptide Synthesis of DOTA-TATE and DOTA-*linker*-TATE Derivatives as a Simple and Low-Cost Method for the Facile Synthesis of Chelator-Peptide Conjugates

Shvan J. Raheem¹, Benjamin W. Schmidt¹, Viswas Raja Solomon¹, Akam K. Salih¹, Eric W. Price^{*1}

¹ Department of Chemistry, University of Saskatchewan, Saskatoon, SK, S7N-5C9, Canada.

*Corresponding author

Eric W. Price, Department of Chemistry, 110 Science Place, University of Saskatchewan, SK, S7N-5C9, Canada, Email: eric.price@usask.ca Phone: +1.306.966.4788, Fax: +1.306.966.4666

Key words: chelator conjugation, radiometals, radiochemistry, peptide-receptor radionuclide therapy, solid-phase peptide synthesis, ultrasonic synthesis, ultrasonic agitation, DOTA-TATE, DOTATATE, Netspot, Lutathera, octreotate, octreotide, somatostatin, Peptide cyclization

Table of contents figure



Table of Content

General Synthesis of DOTA-TATE using Mechanical Agitation and I ₂ for cyclization	. 2
Cyclization using Thallium(III) Oxidation	5
Cyclization using Dimethyl sulfoxide Oxidation	6
Cyclization using H ₂ O ₂ Oxidation	. 7
General Synthesis of DOTA-TATE Using Ultrasound Approach	. 7
Total Synthesis of Fmoc-NH-PEG ₂ -COOH	9
Synthesis of DOTA-tris(tert-butyl)-COOH	15
Radiolabeling of DOTA-TATE with [⁶⁸ Ga]Ga ³⁺ and Purification	21
References	22

1. General Synthesis of DOTA-TATE using Mechanical Agitation and I₂ for cyclization

Table S1: Sequence of amino acid coupling reactions with their optimized coupling times and agents, as performed with 50 mg pre-loaded with 1st amino acid Wang resin (Capacity = 0.8 g/mol), 780 µL DMF, and 100 µL DIEA, with manual agitation (shaking) at ambient temperature.

Coupling	Amino Acid	Amino Acid	Peptide Coupling	Coupling
Step #		Weight (mg)	Agent	Time (min)
1	Fmoc-Cys(Acm)-OH	66	HBTU	40
2	Fmoc-Thr(<i>t</i> -Bu)-OH	64	HBTU	40
3	Fmoc-Lys(Boc)-OH	75	HATU	120
4	Fmoc-D-Trp(Boc)-OH	84	HBTU	100
5	Fmoc-Tyr(t-Bu)-OH	74	HBTU	40
6	Fmoc-Cys(Acm)-OH	66	HBTU	40
7	Fmoc-D-Phe-OH	62	HBTU	40
8	DOTA-tri (tBu-ester)	92	HBTU	120



Figure S1: Qualitative color-based Kaiser test, transparent or pale yellow beads indicate successful coupling (**a**), blue to violet beads indicate the presence of free amine and the coupling failed (**b**).



Figure S2: Semi-Prep HPLC UV/Vis trace of crude DOTA-TATE before purification using I_2 for cyclization.



Figure S3: Analytical HPLC UV/Vis trace of purified DOTA-TATE using I₂ for cyclization.



Figure S4: ESI-MS spectrum of pure DOTA-TATE using I₂ for cyclization.

2. Cyclization using thallium (III) Oxidation.



Figure S5: Semi-Prep HPLC UV/Vis trace of crude DOTA-TATE before purification using Tl(CF₃CO₂)₃ for cyclization.

3. Cyclization using Dimethyl Sulfoxide Oxidation.



Figure S6: Semi-Prep HPLC UV/Vis trace of crude DOTA-TATE before purification using DMSO for cyclization.

4. Hydrogen Peroxide Oxidation.



Figure S7: Semi-Prep HPLC UV/Vis trace of crude DOTA-TATE before purification using H_2O_2 for cyclization.

5. General Synthesis of DOTA-TATE Using Ultrasound Approach.

Table S2: Sequence of amino acid coupling reactions with their optimized coupling times and agents, as performed with 50 mg Wang resin (Capacity = 0.8 g/mol), 780 µL DMF, and 100 µL DIEA, with 4 molar equivalents of reagents for each step and ultrasonic agitation at 25-30 degrees Celsius.

Coupling	Amino Acid	Amino Acid	Peptide Coupling	Coupling
Step #		weight (mg)	Agent	Time (min)
1	Fmoc-Cys(Acm)-OH	66	HBTU	5
2	Fmoc-Thr(<i>t</i> -Bu)-OH	64	HBTU	5
3	Fmoc-Lys(boc)-OH	75	HBTU	5
4	Fmoc-D-Trp(boc)-OH	84	HBTU	10
5	Fmoc-Tyr(<i>t</i> -Bu)-OH	74	HBTU	10
6	Fmoc-Cys(Acm)-OH	66	HBTU	10
7	Fmoc-D-Phe-OH	62	HBTU	10
8	DOTA-tri (tBu-ester)	92	HBTU	15

Table S3: Sequence of amino acid coupling reactions with their optimized coupling times and agents, as performed with 50 mg Wang resin (Capacity = 0.8 g/mol), 399 µL DMF, and 65 µL DIEA, with 2 molar equivalents of reagents for each step ultrasonic agitation at 25-30 degrees Celsius.

Coupling	Amino Acid	Amino Acid	Peptide Coupling	Coupling
Step #		weight (mg)	Agent	Time (min)
1	Fmoc-Cys(Acm)-OH	33	HBTU	5
2	Fmoc-Thr(<i>t</i> -Bu)-OH	32	HBTU	5
3	Fmoc-Lys(boc)-OH	38	HBTU	5
4	Fmoc-D-Trp(boc)-OH	42	HBTU	10
5	Fmoc-Tyr(<i>t</i> -Bu)-OH	37	HBTU	10
6	Fmoc-Cys(Acm)-OH	33	HBTU	10
7	Fmoc-D-Phe-OH	31	HBTU	10
8	DOTA-tri (tBu-ester)	46	HBTU	15



Figure S8: Semi-Prep HPLC UV/Vis trace of crude DOTA-TATE before purification using ultrasonic agitation and I_2 for cyclization.



Figure S9: Analytical HPLC UV/Vis trace of pure DOTA-TATE using ultrasonic agitation and I₂ for cyclization.

6. Total Synthesis of Fmoc-NH-PEG₂-COOH

2-(2-(dibenzylamino)ethoxy)ethanol (P1): Synthesis was carried out according to a literature procedure with minor modifications.¹ Both of 2-(aminoethoxy)ethanol (1.0 g, 9.5 mmol) and potassium carbonate (3.3 g, 23.7 mmol) were stirred in acetonitrile (50 mL) at room temperature, followed by addition of benzyl bromide (2.7 mL, 1.9 mmol), and were then stirred for 20 hours at 50 °C. Potassium carbonate was removed by filtration and the filtrate was reduced to a solid residue using a rotary evaporator under *vacuo*. The solid residue was dissolved in hydrochloric acid (0.1 M) and washed with ethyl acetate (2 × 10 mL). The aqueous layer was basified with sodium hydroxide (1 M) and extracted with dichloromethane (4 × 10 mL). The solvent was dried (MgSO₄) and removed under *vacuo*, to give **P1**, (2.3 g, 85%).¹H NMR (500 MHz, CDCl₃) δ (ppm): 2.70 (t, 2H, *J*=5.9 Hz),

3.49 (t, 2H, J=4.7 Hz), 3.59 (t, 2H, J=5.9 Hz), 3.60-3.70 (m, 6H), 7.24-7.40 (m, 10H). ¹³C NMR (CDCl3) δ(ppm): 52.97, 59.00, 61.89, 69.64, 72.10, 127.02, 128.29, 128.92, 139.40. LRMS-ESI *m/z* calcd for [C₁₈H₂₃NO₂ + H]⁺: 286.1, found: 285.9.



Figure S10: ¹H NMR spectrum of P1 in CDCl₃.



Figure S11: ¹³C NMR Spectrum of P1 in CDCl₃.

2-(2-(2-(dibenzylamino)ethoxy)ethoxy)acetic acid (P2): In a Schlenk flask, NaH (1.2 g, 28.8 mmol; 60% dispersion in oil) was washed twice with 15 mL hexane under N₂ then dry THF (14 mL) was added at 0 °C. This was followed by addition of **P1** (2.05 g, 7.2 mmol) dropwise and kept stirring at 0 °C for a half an hour. Alpha bromo acetic acid (1.5 g, 10.8 mmol) was added dropwise and the mixture was refluxed overnight. Carefully, 1 mL of H₂O was added dropwise and the reaction was left stirring for 5 minutes at room temperature, then extra H₂O (20 mL) was added. The aqueous layer was washed with a mixture of hexane/diethyl ether 1:1, (2 × 15 mL). The aqueous solution was acidified to pH 2-3 with hydrochloric acid (1 M) and washed with diethyl ether (3 × 10 mL), then neutralized to pH 6-7 with NaOH (1 M). Solid sodium chloride was added and the mixture was extracted with DCM (5 × 150 mL). The solvent was dried and removed under *vacuo*, the crude product **P2** was used in the next reaction without further purification (1.2 g, 61%). ¹H NMR (500 MHz, CDCl₃) δ (ppm): 2.85 (t, 2H, *J* = 5.6 Hz), 3.54 (t, 2H, *J* =

5.6 Hz), 3.66-3.68 (m, 4H), 3.93 (s, 4H), 4.08 (s, 2H), 7.27-7.33 (m, 10H), 11.4 (s, 1H). ¹³C NMR (CDCl₃) δ(ppm): 51.33, 53.50, 58.18, 68.13, 69.60, 70.16, 70.46, 127.98, 128.56, 129.94, 135.53, 174.42. LRMS-ESI *m/z* calcd for [C₂₀H₂₅NO₄ + H]⁺:344.18, found: 344.1.



Figure S12: ¹H NMR spectrum of P2 in CDCl₃.



Figure S13: ¹³C NMR spectrum of P2 in CDCl₃.

2-(2-(2-aminoethoxy)ethoxy)acetic acid (P3): Both of P2 (1.14 g, 3.31 mmol) and palladium (280 mg; 10% Pd/C) were dissolved in methanol (20 mL). The mixture was transferred in to a hydrogenator and stirred under H₂ at 30 psi for 12 hours. The completion of the reaction was confirmed by TLC and the catalyst was removed by filtration through celite powder. The solvent was removed under *vacuo* and the residue was triturated with cold diethyl ether (20 mL) to give P3 (453 mg, 85%). ¹H NMR (500 MHz, MeOD) δ (ppm): 3.10 (t, 2H, *J*=5.1 Hz), 3.62 (t, 2H, *J*= 6.1 Hz), 3.69 (t, 2H, *J*= 6.1 Hz), 3.73 (t, 2H, *J*= 5.1 Hz), 3.88 (s, 2H). LRMS-ESI *m/z* calcd for [C₆H₁₃NO₄ + H]⁺:164.09, found: 164.1.



Figure S14: ¹H NMR Spectrum of P3 in MeOD.

1-(9H-fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oic acid (P4): A mixture of P3 (450 mg, 2.75 mmol) and potassium carbonate (763 mg, 5.52 mmol) were stirred for 10 minutes in H₂O (10 mL). This was followed by addition of Fmoc-*N*-hydroxysuccinimide ester (1.03 g, 3.05 mmol) and stirred at 40 °C for 16 hours. The pH should be adjusted to 9 before washing with diethyl ether (2 × 5 mL). The aqueous solution was acidified (pH ~2) by HCl (1 M) then extracted with DCM (5 × 5 mL). The organic solvent was removed and the solid residue was recrystallized from acetonitrile to obtain P4 (511.4 mg, 51%). ¹H NMR (500 MHz, MeOD) δ (ppm): 3.28 (t, 2H, *J* =5.4 Hz), 3.51 (t, 2H, *J*=5.4 Hz), 3.60-3.62 (m, 2H), 3.67-3.68 (m, 2H), 4.11 (s, 2H), 4.08 (t, 1H, *J*=6.8 Hz), 4.33 (d, 2H, *J*=6.9 Hz), 7.28-7.78 (m, 10H). ¹³C NMR (CDCl3) δ (ppm): 41.69, 67.67, 69.02, 70.91, 71.28, 71.75, 120.9, 126.17, 128.12,

128.74, 142.57, 145.31, 158.89, 174.02 . LRMS-ESI m/z calcd for $[C_{21}H_{23}NO_6 + Na]^+$:408.1, found: 407.9.



Figure S15: ¹H NMR Spectrum of P4 in MeOD.



Figure S16: ¹³C NMR spectrum of P4 in MeOD.

7. Synthesis of DOTA-tris(tert-butyl)-COOH.

Benzyl-2-bromoacetate (D1): Synthesis was carried out according to a literature procedure.² A solution of benzyl alcohol (0.39 g, 3.6 mmol), *p*-toluenesulfonic acid (0.007 g, 0.036 mmol), and bromoacetic acid (0.50 g, 3.6 mmol) in toluene (20 mL) was stirred at 120 °C for 24 hours with continuous H₂O removal by using a Dean-Stark trap. The solvent was removed and the residue was purified using silica chromatography (Hexane: EtOA gradient 10%-50% EtOA) to give (**D1**) as a yellow oil (0.452 g, 55%). ¹H NMR (500 MHz, CDCl₃) δ (ppm): 3.87 (s, 2H), 5.21 (s, 2H), 7.35-7.39 (m, 5H). ¹³C NMR (CDCl3) δ (ppm): 25.19, 67.97, 128.4, 128.6, 128.7, 135.0, 167.1. HRMS-ESI *m/z* calcd for [C₉H₉BrO₂+ H]⁺: 228.9864, found: 228.9830.



Figure S17: ¹H NMR Spectrum of D1 in CDCl₃.

Tri-tert-butyl-2,2',2''-(10-(2-(benzyloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)

triacetate (D2): To a commercially available 1,4,7,10-tetraazacyclododecane-1,4,7-tris(t-butyl acetate) (**DO3A**, Macrocyclics) (0.100 g, 0.194 mmol), both of benzyl-2-bromoacetate (**D1**) (0.0470 g, 0.204 mmol) and potassium carbonate (0.0540 g, 0.388 mmol) were added with anhydrous CH₃CN (10 mL) and stirred for 12 hours at room temperature. After 12 hours, the solvent was removed by rotary evaporation under *vacuo* and the solid residue was purified immediately with silica chromatography (DCM: MeOH 90:10%), to give (**D2**) as yellow oil (0.104 g, 81%). ¹H NMR (500 MHz, CDCl₃) δ (ppm): 1.42 (s, 27H),2.12-3.40 (b, 24H), 5.08 (s, 2H), 7.26-732 (m, 5H). ¹³C NMR (CDCl3) δ (ppm): 27.76, 50.28, 54.86, 55.58, 66.71, 66.79, 81.89, 128.0, 128.3, 128.5, 134.9, 172.1, 173.4. HRMS-ESI *m/z* calcd for [C₃₅H₅₈N₄O₈+ H]⁺: 663.4333, found: 662.4267.



Figure S18: ¹H NMR Spectrum of D2 in CDCl₃.



Figure S19: ¹³C NMR spectrum of D2 in CDCl₃.



Figure S20: HR ESI-MS spectrum of D2 in CDCl₃.

2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (D3): Both of D2 (0.100 g, 0.151 mmol) and palladium (0.016 g; 10% Pd/C) were dissolved in methanol (10 mL). The mixture was transferred in to a hydrogenator and stirred under H₂ at 30 psi for 5 hours. The completion of the reaction was confirmed by TLC and the catalyst was removed by filtration through celite powder. The solvent was removed by rotary evaporation under *vacuo* and the residue was purified immediately using silica chromatography (DCM: MeOH 90:10%) to give D3 as a pale yellow solid (0.080 g, 91 %). ¹H NMR (500 MHz, CDCl₃) δ(ppm): 1.43 (s, 27H), 2.02 (s, 2H), 2.78 (s, 8H), 3.04 (s, 4H), 3.31 (s, 4H), 3.39 (s, 2H), 3.62 (s, 2H), 3.72 (s, 2H). ¹³C NMR (CDCl3) δ(ppm): 28.19, 48.57, 50.31, 53.48, 55.77, 56.86, 81.87, 163.26, 167.30, 170.00, 170.73. HRMS-ESI *m/z* calcd for $[C_{28}H_{52}N_4O_8+H]^+$: 573.3863, found:573.3840.



Figure S21: ¹H NMR Spectrum of D3 in CDCl₃.



Figure S22: ¹³C NMR spectrum of D3 in CDCl₃.



Figure S23: HR ESI-MS spectrum of D3 in CDCl₃.

8. Radiolabeling of DOTA-TATE with [68Ga]Ga³⁺.



Figure S24: Radio-iTLC profile of $[{}^{68}Ga]Ga^{3+}$ (left) and $[{}^{68}Ga]Ga$ -DOTA-TATE (right) eluted with 1.0 M ammonium acetate and methanol (1:1) mobile phase.



Figure S25: Reverse phase C-18 HPLC UV/Vis chromatogram for non-radiolabeled DOTA-TATE, R_T =10.42 min, Purity > 95%.



Figure S26: Radio-HPLC chromatogram for radiolabeled [68 Ga]Ga-DOTA-TATE, R_T =10.37 min, RCP > 95%.

References

- (1) Visintin, C., Aliev, A. E., Riddall, D., Baker, D., Okuyama, M., Hoi, P. M., Hiley, R., and Selwood, D. L. (2005) Membrane Receptor Probes: Solid-Phase Synthesis of Biotin-Asp-PEG-arvanil Derivatives. *Org. Lett.* 7 (9), 1699-1702.
- (2) Itoh, T., Mishiro, M., Matsumoto, K., Hayase, S., Kawatsura, M., and Morimoto, M. (2008) Synthesis of fulleropyrrolidine–imidazolium salt hybrids and their solubility in various organic solvents. *Tetrahedron 64 (8)*, 1823-1828.